S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
NASDAQ:BCDA

BioCardia (BCDA) Stock Price, News & Analysis

$0.38
+0.01 (+2.72%)
(As of 04/18/2024 ET)
Today's Range
$0.36
$0.38
50-Day Range
$0.36
$0.58
52-Week Range
$0.36
$2.92
Volume
62,010 shs
Average Volume
120,945 shs
Market Capitalization
$10.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

BioCardia MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
961.0% Upside
$4.00 Price Target
Short Interest
Healthy
1.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Balanced
Insiders Both Buying and Selling
Proj. Earnings Growth
Decreasing
From ($0.42) to ($0.49) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.68 out of 5 stars

Medical Sector

628th out of 918 stocks

Biological Products, Except Diagnostic Industry

102nd out of 147 stocks

BCDA stock logo

About BioCardia Stock (NASDAQ:BCDA)

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

BCDA Stock Price History

BCDA Stock News Headlines

Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
BioCardia Full Year 2023 Earnings: Misses Expectations
Preview: BioCardia's Earnings
BioCardia is about to announce its earnings — here's what to expect
Q4 2023 BioCardia Inc Earnings Call
BioCardia: Q4 Earnings Insights
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
BioCardia Inc.
BCDA Mar 2024 1.500 call
BCDA Aug 2024 0.500 call
BCDA Mar 2024 0.500 call
See More Headlines
Receive BCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCardia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/18/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:BCDA
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+961.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-11,570,000.00
Net Margins
-2,425.79%
Pretax Margin
-2,425.79%

Debt

Sales & Book Value

Annual Sales
$480,000.00
Book Value
($0.07) per share

Miscellaneous

Free Float
20,344,000
Market Cap
$10.13 million
Optionable
Optionable
Beta
1.47
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

BCDA Stock Analysis - Frequently Asked Questions

Should I buy or sell BioCardia stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioCardia in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BCDA shares.
View BCDA analyst ratings
or view top-rated stocks.

What is BioCardia's stock price target for 2024?

2 brokers have issued 12 month price targets for BioCardia's shares. Their BCDA share price targets range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 961.0% from the stock's current price.
View analysts price targets for BCDA
or view top-rated stocks among Wall Street analysts.

How have BCDA shares performed in 2024?

BioCardia's stock was trading at $0.6642 at the start of the year. Since then, BCDA shares have decreased by 43.2% and is now trading at $0.3770.
View the best growth stocks for 2024 here
.

Are investors shorting BioCardia?

BioCardia saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 535,900 shares, a drop of 46.9% from the March 15th total of 1,010,000 shares. Based on an average daily volume of 372,500 shares, the short-interest ratio is currently 1.4 days.
View BioCardia's Short Interest
.

When is BioCardia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our BCDA earnings forecast
.

How were BioCardia's earnings last quarter?

BioCardia, Inc. (NASDAQ:BCDA) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.05. The company had revenue of $0.82 million for the quarter, compared to the consensus estimate of $0.04 million. BioCardia had a negative trailing twelve-month return on equity of 3,638.68% and a negative net margin of 2,425.79%. During the same period last year, the company posted ($0.30) EPS.

When did BioCardia's stock split?

BioCardia shares reverse split on the morning of Friday, November 3rd 2017. The 1-12 reverse split was announced on Thursday, November 2nd 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 2nd 2017. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of BioCardia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCardia investors own include Arotech (ARTX), CytoDyn (CYDY), China Gold International Resources (CGG), BioSolar (BSRC), Blink Charging (BLNK), Aurcana Silver (AUNFF), RecycLiCo Battery Materials (AMY) and

When did BioCardia IPO?

BioCardia (BCDA) raised $51 million in an initial public offering on the week of July 20th 2015. The company issued 3,900,000 shares at $12.00-$14.00 per share. Cantor Fitzgerald & Co. served as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers.

How do I buy shares of BioCardia?

Shares of BCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCDA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners